Dr. Mei X. Wu received her Ph.D. from Utah State University in 1992, after which she was trained as a post-doctoral fellow at Massachusetts Institute of Technology (MIT) and then at Dana-Farber Cancer Institute, Harvard Medical School (HMS). She became an instructor in 1995 at HMS and an assistant professor in 1999 at Baylor College of Medicine. She relocated to Massachusetts General Hospital/HMS in 2003. Her laboratory studies the molecular mechanisms and signaling pathways in association with autoimmune diseases, protective immune responses, and immune-suppression.
One of the major focuses in her laboratory is the study of the biological function of a stress-responsive gene named Immediate Early responsive gene X-1 (IEX-1). IEX-1 is one of the cell survival genes regulated by the NFκB transcription factor. IEX-1 targets an intrinsic inhibitor for mitochondrial FoF1-ATPase named IF1 to degradation, which distinguishes IEX-1 from other anti-apoptotic genes like the Bcl-2 family.
Another line of research in her laboratory is to unravel a complex interaction between Gαi2- and Gαi3-dependent signaling in directing lymphocyte trafficking in vivo. Her laboratory takes advantage of many newly-developed technologies at Wellman to answer questions pivotal to the modulation of immune response.
Dr. Wu’s research has been continuously supported by various competitive funds from the National Institutes of Health (NIH), the Department of Defense, the American Cancer Society, the Crohn’s & Colitis Foundation of America, and the American Heart Association. Dr. Wu was named an American Cancer Society Research Scholar in 2003 and the recipient of the Senior Research Award from the Crohn’s & Colitis Foundation of America in 2007. She also received an Independent Scientist Award from NIH in 2006.
Harvard Medical School
Andrea L. Brissette